Borderline Leprosy

Subscribe to Selected New Research on Borderline Leprosy

57 relevant articles (1 outcomes, 5 trials/studies) found for this Disease

Description: A form of LEPROSY in which there are clinical manifestations of both principal types (lepromatous and tuberculoid). The disease may shift toward one of these two polar or principal forms.

Also Known As:

Leprosy, Borderline; Borderline Leprosies; Dimorphous Leprosies; Dimorphous Leprosy; Leprosies, Borderline; Leprosies, Dimorphous; Leprosy, Dimorphous

Relationship Network

Disease Context: Research Results

Bacterial Infections and Mycoses

Bacterial Infections: 6387

Gram-Positive Bacterial Infections: 86

Actinomycetales Infections: 1

Mycobacterium Infections: 21

Leprosy: 4010

Borderline Leprosy: 57

Related Diseases

1.	Lepromatous Leprosy
2.	Neuritis (Polyneuritis)
3.	Tuberculoid Leprosy
4.	Leprosy (Hansen's Disease)
5.	Erythema Nodosum

Experts

1.	Britton, S: 2 articles (03/2004 - 11/2001)
2.	Schön, T: 2 articles (03/2004 - 11/2001)
3.	Sundqvist, T: 2 articles (03/2004 - 11/2001)
4.	Negesse, Y: 2 articles (03/2004 - 11/2001)
5.	Baquera-Heredia, J: 1 article (03/2004)
6.	Eon-Contreras, J C L: 1 article (03/2004)
7.	Hernández-Pando, R: 1 article (03/2004)
8.	Becerril-Villanueva, L E: 1 article (03/2004)
9.	Radhakrishnan, K: 1 article (06/2003)
10.	Bhat, Ramesh M: 1 article (06/2003)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Borderline Leprosy:

1.	Prednisone (Sone)FDA LinkGeneric 09/01/1998 - "Contribution of type 1 reactions to sensory and motor function loss in borderline leprosy patients and the efficacy of treatment with prednisone." Order ALL the reference details at left...
2.	LeprominIBA 09/01/1999 - "The lepromin test was positive in six (31.58%) patients; four were of the tuberculoid group and one each from the indeterminate and borderline leprosy groups" 03/01/1997 - "The control group III consisted of 50 lepromin-positive, borderline leprosy patients not given any immunostimulation but given only MDT" 03/01/1997 - "The control group II consisted of 25 lepromin-negative, borderline leprosy patients given BCG vaccination plus MDT and 25 lepromin-negative, borderline leprosy patients given killed Mycobacterium leprae (human) vaccine plus MDT" 10/01/1981 - "Therapy of tuberculoid and borderline leprosy by specific progressive desensitization to lepromin" 09/01/1979 - "In vitro immunologic changes in 6 lepromatous leprosy or borderline leprosy patients treated with BCG alone or BCG and lepromin for 12 to 20 months, followed by BCG and antibiochemotherapy for 1 to 2 years]" Order ALL the reference details at left...
3.	AntibodiesIBA 01/01/1977 - "Moreover, antihuman globulin was consumed more intensely by the antispermatozoal antibodies present in the sera in the lepromatous than in the tuberculoid and borderline leprosy groups." 09/01/1984 - "However, the percentage of positive FLA-ABS tests caused by salivary IgA antibodies was higher in the patients with tuberculoid or borderline leprosy than in those with lepromatous leprosy" 11/01/2001 - "OBJECTIVES: The aim of this study was to investigate the presence of local production of NO and peroxynitrite in borderline leprosy by using antibodies against iNOS and the product of peroxynitrite, nitrotyrosine (NT)" Order ALL the reference details at left...
4.	Peroxynitrous Acid (Peroxynitrite)IBA 03/01/2004 - "CONCLUSIONS: Our results suggest that NO and peroxynitrite could be involved in the nerve damage following borderline leprosy." 11/01/2001 - "OBJECTIVES: The aim of this study was to investigate the presence of local production of NO and peroxynitrite in borderline leprosy by using antibodies against iNOS and the product of peroxynitrite, nitrotyrosine (NT)" Order ALL the reference details at left...
5.	Rifampin (Rifampicin)FDA LinkGeneric 09/01/1994 - "In the course of a clinical trial designed to re-examine the bactericidal efficiency of 600-mg doses of rifampin (RMP) against Mycobacterium leprae, two doses of RMP, either 600 mg or 1200 mg, were administered 28 days apart to 29 previously untreated patients with lepromatous or borderline leprosy" 06/01/1975 - "Treatment of neuritis in borderline leprosy with rifampicin and corticosteroids--a pilot trial." Order ALL the reference details at left...
6.	3-nitrotyrosineIBA 03/01/2004 - "Nitrotyrosine localization to dermal nerves in borderline leprosy." 11/01/2001 - "Expression of inducible nitric oxide synthase and nitrotyrosine in borderline leprosy lesions." 11/01/2001 - "OBJECTIVES: The aim of this study was to investigate the presence of local production of NO and peroxynitrite in borderline leprosy by using antibodies against iNOS and the product of peroxynitrite, nitrotyrosine (NT)" Order ALL the reference details at left...
7.	LipidsIBA 01/01/1964 - "STUDIES ON LIPIDS IN 'BORDERLINE' LEPROSY." Order ALL the reference details at left...
8.	Adrenal Cortex Hormones (Corticosteroids)IBA 06/01/1975 - "Treatment of neuritis in borderline leprosy with rifampicin and corticosteroids--a pilot trial." Order ALL the reference details at left...
9.	anti-leprosy vaccineIBA 03/01/1997 - "The test Group I, consisting of 50 lepromin-negative, borderline leprosy patients, were given low-dose Convit vaccine plus MDT" 03/01/1997 - "Immunotherapy of lepromin-negative borderline leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta." 03/01/1997 - "The present report, which describes management of lepromin-negative borderline leprosy patients with low-dose Convit vaccine, is an extension of our earlier study on the treatment of lepromatous leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy (MDT)" Order ALL the reference details at left...
10.	Dapsone FDA Link 01/01/1977 - "Borderline leprosy reactions and dapsone." 11/27/1976 - "Evidence for prevention of borderline leprosy reactions by dapsone." 06/01/1976 - "Serial observations on cutaneous sensation and on sweat response in hypopigmented flat patches of twenty-nine patients with tuberculoid and five with dimorphous leprosy on dapsone therapy were studied over 2 years" 04/01/2006 - "While polar types of leprosy (TT & LL) were common in the dapsone era, more of borderline leprosy (BT & BL) cases was seen more recently" 06/01/2003 - "A case report of fatal dapsone-induced agranulocytosis in an Indian mid-borderline leprosy patient." Order ALL the reference details at left...

Therapies and Procedures

1.	Immunotherapy 07/01/1981 - "Result of studies of immunotherapy of lepromatous leprosy and borderline leprosy]" 03/01/1997 - "Immunotherapy of lepromin-negative borderline leprosy patients with low-dose Convit vaccine as an adjunct to multidrug therapy; a six-year follow-up study in Calcutta." Order ALL the reference details at left...
2.	Aftercare (After-Treatment) 07/01/1998 - "The individuals studied were: 5 borderline leprosy (BB) patients, 4 with a lepromatous leprosy (LL), all of whom were undergoing epidemiological surveillance after treatment and 44 household contacts: 21 of the LL and 23 contacts of the BB patients" 05/01/1971 - "Bacilli from a number of tissues excised from cases of lepromatous and borderline leprosy, unlike mycobacteria, were found to lose their acid-fastness after treatment with pyridine." Order ALL the reference details at left...
3.	Chemoprevention 12/01/1989 - "The onset of a skin lesion of borderline leprosy in a boy 3 months after chemoprophylaxis raises the question of the nature of such a skin lesion and, indirectly, of the effectiveness of the chemoprophylaxis." Order ALL the reference details at left...
4.	Transplantation (Transplant Recipients) 03/01/1993 - "The other two cases presented with lepromatous and borderline (dimorphous) leprosy 5 months and 5 years after transplantation, respectively" Order ALL the reference details at left...
5.	Drug Therapy (Chemotherapy) 09/14/1991 - "42 (31%) of 136 Nepalese borderline leprosy patients (97 male, 39 female; age range 7-73 years) had a type-1 reaction during the first 2 years of multi-drug therapy" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Borderline Leprosy

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1 Outcomes
Top 200 Key Drugs and Biologics
Top 5 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>